Aspect Biosystems is a Canadian biotechnology company pioneering the development of bioprinted tissue therapeutics. Their transformative platform technology integrates proprietary bioprinting, therapeutic cells, biomaterials, and computational design to create allogeneic tissue therapeutics aimed at replacing damaged organ functions. The company collaborates with leading pharmaceutical and biotech firms to address significant challenges in regenerative medicine, positioning itself as a key player in the field. With a diverse team of innovators, Aspect has raised over $200M in capital and is focused on delivering groundbreaking solutions for currently incurable diseases.
Climate Ai is a pioneering enterprise climate resilience platform that utilizes artificial intelligence to help businesses across the food and agriculture value chain mitigate climate risks and seize new opportunities. With patented models and hyper-local climate insights, Climate Ai enables companies to make informed decisions, adapt operations, and enhance supply chain reliability. The platform has been adopted in over 50 countries, climate-proofing more than 1000 locations, and is recognized for its innovative approach to climate adaptation, making it a leader in the industry.
Cohere is a platform that gives developers and businesses access to NLP, powered by the innovative generation of large language models. Cohere is used to build machines that understand the world and make it safely accessible to all. Cohere provides access to affordable, easy-to-deploy large language models. Its platform gives computers the ability to read and write.
Crossing Minds is a cutting-edge AI platform that specializes in personalized information retrieval and recommendations for enterprises. Leveraging advanced embeddings, large-scale training, and proprietary RAG technologies, the platform delivers real-time, scalable performance tailored to complex databases and unique use cases. With a focus on enhancing customer engagement through personalized recommendations, Crossing Minds has demonstrated significant traction in various industries, including e-commerce and financial institutions, by driving substantial increases in sales and conversion rates. Their technology is designed for enterprises that require customized solutions, ensuring accurate data processing and enriched insights for improved decision-making.
DatologyAI is an AI-data curation startup that specializes in automated data curation for generative AI. Their product optimizes training efficiency, maximizes performance, and reduces compute costs by providing fully automated data curation that integrates seamlessly into existing infrastructures. The solution is modality-agnostic, capable of handling various data types without requiring labels, and is designed to scale with datasets of petabytes or more. With a world-class team and backing from prominent venture funds, DatologyAI positions itself as a leader in the AI data curation market, catering to businesses looking to enhance their AI capabilities securely and efficiently.
Firsthand is transforming how advertisers and publishers attract, inspire, and engage consumers through AI-powered Brand Agents. The platform combines Lakebed™, an AI-first data rights management solution, with custom-built Brand Agents that deliver dynamic, personalized experiences to consumers in real-time. This innovative approach allows brands to maintain control over their data and customer interactions while gaining valuable insights into consumer behavior. Founded by pioneers in digital advertising, Firsthand aims to empower companies to thrive in the AI era by fostering direct connections with consumers without intermediaries.
Genesis Therapeutics is leveraging an advanced molecular AI platform, GEMS, to discover and develop highly potent and selective drugs for challenging protein targets. The company focuses on using AI and physics research to synthesize drug candidates with unprecedented speed and efficacy, positioning itself as a leader in the biotech industry. With a strong emphasis on collaboration among interdisciplinary teams, Genesis aims to revolutionize drug discovery and improve patient outcomes. Their recent strategic collaborations and significant funding rounds highlight their traction and market position in the competitive landscape of drug development.
Graft is a Modern AI platform enabling data teams to build production-ready AI solutions in a few clicks. No machine learning skills, no need to hire a team, and no infrastructure to build or maintain. Take a data-centric approach that leverages foundation models to drive better business outcomes today.